CERVOMED INC (CRVO)
US15713L1098 - Common Stock
CERVOMED INC
NASDAQ:CRVO (12/18/2024, 1:35:04 PM)
2.02
+0.08 (+4.12%)
Company Profile
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-11-09. The company is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. The company is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Company Info
CERVOMED INC
20 Park Plaza, Suite 424
Boston MASSACHUSETTS
P: 16177444400
Employees: 8
Website: https://cervomed.com/
CRVO News
6 days ago - CervoMed Inc.CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for...
8 days ago - ChartmillWhat's going on in today's sessionStay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
8 days ago - ChartmillWhat's going on in today's sessionTop movers in Tuesday's session
8 days ago - Yahoo FinanceCervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock PlummetsOn Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (a measure of dementia severity) or any of its key secondary endpoints – change from baseline in Timed Up and Go (measures a person’s mobility, balance, a
8 days ago - ChartmillGapping stocks in Tuesday's sessionTraders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.
8 days ago - ChartmillGet insights into the top gainers and losers of Tuesday's pre-market session.Top movers in Tuesday's pre-market session
CRVO Twits
Here you can normally see the latest stock twits on CRVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
